Comparative Pharmacology
Head-to-head clinical analysis: COMTAN versus ONGENTYS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COMTAN versus ONGENTYS.
COMTAN vs ONGENTYS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective and reversible inhibitor of catechol-O-methyltransferase (COMT), which inhibits the metabolism of levodopa to 3-O-methyldopa, thereby increasing the plasma half-life and bioavailability of levodopa in the brain.
Ongentys (opicapone) is a selective and reversible inhibitor of catechol-O-methyltransferase (COMT). By inhibiting COMT, it decreases the metabolism of levodopa to 3-O-methyldopa, thereby increasing plasma levodopa levels and enhancing its bioavailability in the brain, leading to improved dopaminergic effects.
200 mg orally once daily, increased to 200 mg three times daily as tolerated, with each dose of levodopa/carbidopa; maximum 200 mg per dose.
50 mg orally once daily, taken at bedtime.
None Documented
None Documented
Terminal elimination half-life is approximately 0.4 to 0.7 hours (mean 0.7 hours) in plasma, but the pharmacodynamic half-life (COMT inhibition) is longer, about 2-4 hours, supporting thrice-daily dosing.
The terminal elimination half-life of opicapone is approximately 1 to 2 hours at low doses, but at therapeutic doses (50 mg) it exhibits nonlinear pharmacokinetics with an effective half-life of about 12 to 16 hours due to tight binding to COMT enzyme, allowing once-daily dosing.
Primarily fecal (90%) as unchanged drug; renal excretion accounts for approximately 10%, mostly as glucuronide conjugates.
Following oral administration, approximately 30% of the dose is excreted in urine as unchanged opicapone, with an additional 10% as glucuronide conjugates. The remainder is eliminated via biliary/fecal routes, accounting for about 60% of the dose.
Category C
Category C
COMT Inhibitor
COMT Inhibitor